Imagion Biosystems Ltd
ASX:IBX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Imagion Biosystems Ltd
ASX:IBX
|
AU |
|
PVR INOX Ltd
NSE:PVRINOX
|
IN |
|
Eestech Inc
OTC:EESH
|
US |
|
MyState Ltd
ASX:MYS
|
AU |
|
Hexagon AB
OTC:HXGBF
|
SE |
|
Novogene Co Ltd
SSE:688315
|
CN |
|
Zhejiang Chint Electrics Co Ltd
SSE:601877
|
CN |
|
China Zhonghua Geotechnical Engineering Group Co Ltd
SZSE:002542
|
CN |
|
X
|
Xinjiang International Industry Co Ltd
SZSE:000159
|
CN |
|
Electricite de France SA
PAR:EDF
|
FR |
|
Yes Bank Ltd
NSE:YESBANK
|
IN |
|
CSR Ltd
ASX:CSR
|
AU |
|
B
|
BEH-Property Co Ltd
SSE:600791
|
CN |
|
IMAX China Holding Inc
HKEX:1970
|
CN |
|
DoubleDown Interactive Co Ltd
NASDAQ:DDI
|
KR |
|
Kerry Logistics Network Ltd
HKEX:636
|
HK |
|
Medprin Regenerative Medical Technologies Co Ltd
SZSE:301033
|
CN |
|
A
|
Allied Copper Corp
XTSX:CPR
|
CA |
|
Huapont Life Sciences Co Ltd
SZSE:002004
|
CN |
Imagion Biosystems Ltd
Imagion Biosystems Ltd. engages in the research and development of non-radioactive and safe diagnostic imaging technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-06-22. The firm's principal activities include nanotechnology, biotechnology, cancer diagnostics and medical imaging using superparamagnetic relaxometry. Its MagSense technology is a functional imaging method for detecting cancers and other critical diseases. MagSense instrument uses sensitive magnetic sensors to detect the tiny bio-safe nanoparticles. MagSense nanoparticles bound to cancer cells act like a magnetic beacon to identify the presence of a tumour. MagSense nanoparticles are supplied as an injectable solution and formulated to provide delivery to specific types of cancer cells. Its PrecisionMRX nanoparticles are developed for magnetic relaxometry and other biomedical applications. The company serves a range of applications, including detecting cancer, monitoring therapy and detecting other diseases. Its MagSense HER2 imaging agent is under phase I clinical study.
Imagion Biosystems Ltd. engages in the research and development of non-radioactive and safe diagnostic imaging technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-06-22. The firm's principal activities include nanotechnology, biotechnology, cancer diagnostics and medical imaging using superparamagnetic relaxometry. Its MagSense technology is a functional imaging method for detecting cancers and other critical diseases. MagSense instrument uses sensitive magnetic sensors to detect the tiny bio-safe nanoparticles. MagSense nanoparticles bound to cancer cells act like a magnetic beacon to identify the presence of a tumour. MagSense nanoparticles are supplied as an injectable solution and formulated to provide delivery to specific types of cancer cells. Its PrecisionMRX nanoparticles are developed for magnetic relaxometry and other biomedical applications. The company serves a range of applications, including detecting cancer, monitoring therapy and detecting other diseases. Its MagSense HER2 imaging agent is under phase I clinical study.
